These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34430850)

  • 1. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series.
    Larussa T; Basile A; Palleria C; Iannelli C; Vero A; Giubilei L; De Sarro C; Suraci E; Marasco R; Imeneo M; Russo E; Abenavoli L; De Sarro G; Luzza F
    Med Pharm Rep; 2021 Jul; 94(3):289-297. PubMed ID: 34430850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project.
    Barbieri MA; Viola A; Cicala G; Spina E; Fries W
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.
    Thomas PWA; Römkens TEH; West RL; Russel MGVM; Jansen JM; van Lint JA; Jessurun NT; Hoentjen F
    United European Gastroenterol J; 2021 Oct; 9(8):919-928. PubMed ID: 34077634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases.
    van Lint JA; Jessurun NT; Hebing RCF; Hoentjen F; Tas SW; Vonkeman HE; van Doorn MBA; Sobels A; Spuls PI; van Puijenbroek EP; Nurmohamed MT; van den Bemt BJF
    Drug Saf; 2020 Sep; 43(9):917-925. PubMed ID: 32451974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy.
    Roberti R; Iannone LF; Palleria C; De Sarro C; Spagnuolo R; Barbieri MA; Vero A; Manti A; Pisana V; Fries W; Trifirò G; Naturale MD; Larussa T; De Francesco AE; Bosco V; Donato di Paola E; Citraro R; Luzza F; Bennardo L; Rodinò S; Doldo P; Spina E; Russo E; De Sarro G
    Curr Med Res Opin; 2020 Sep; 36(9):1457-1463. PubMed ID: 32573307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
    Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study.
    Tallarico M; Palleria C; Ruffolo L; Spagnuolo R; Naturale MD; De Francesco AE; De Sarro C; Romeo R; Citraro R; Doldo P; Abenavoli L; Gallelli L; Luzza F; Leo A; De Sarro G
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network.
    Romeo AC; Ventimiglia M; Dipasquale V; Orlando A; Citrano M; Pellegrino S; Accomando S; Cottone M; Romano C
    Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):223-229. PubMed ID: 31204314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.
    Zelinkova Z; Bultman E; Vogelaar L; Bouziane C; Kuipers EJ; van der Woude CJ
    World J Gastroenterol; 2012 Dec; 18(47):6967-73. PubMed ID: 23322995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD.
    Click B; Barnes EL; Cohen BL; Sands BE; Hanson JS; Rubin DT; Dubinsky MC; Regueiro M; Gazis D; Crawford JM; Long MD
    BMC Gastroenterol; 2022 Feb; 22(1):71. PubMed ID: 35183108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.
    Sassaki LY; Miszputen SJ; Kaiser Junior RL; Catapani WR; Bafutto M; Scotton AS; Zaltman C; Baima JP; Ramos HS; Faria MAG; Gonçalves CD; Guimaraes IM; Flores C; Amarante HMBS; Nones RB; Parente JML; Lima MM; Chebli JM; Ferrari MLA; Campos JF; Sanna MGP; Ramos O; Parra RS; da Rocha JJR; Feres O; Feitosa MR; Caratin RF; Senra JT; Santana GO
    World J Gastroenterol; 2021 Jun; 27(23):3396-3412. PubMed ID: 34163120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
    Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 7-Years Active Pharmacovigilance Study of Adverse Drug Reactions Causing Children Admission to a Pediatric Emergency Department in Sicily.
    Nasso C; Mecchio A; Rottura M; Valenzise M; Menniti-Ippolito F; Cutroneo PM; Squadrito V; Squadrito F; Pallio G; Irrera N; Arcoraci V; Altavilla D
    Front Pharmacol; 2020; 11():1090. PubMed ID: 32765282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.